Trial Profile
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs MEDI 3617 (Primary) ; Tremelimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 28 Apr 2023 Status changed from active, no longer recruiting to completed.
- 30 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 09 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Mar 2023.